Search

In 'Sloan Valve,' Changes to 'Classic' Royalty Analysis Make Expert Vulnerable

Sloan Valve Company v. Zurn Industries, Inc.

Court excludes royalty analysis veering from “classic way” in that expert used number of infringing products, not revenue, as royalty base and dollar amount, not percentage of the revenue, as royalty rate.

Inexact Apportionment Invalidates Expert’s Royalty Calculation

Court excludes plaintiff expert testimony under Daubert, finding both the expert’s royalty base and rate determinations fatally flawed due to the expert’s inexact apportionment; in valuing damages, he failed to compensate only for the infringement caused ...

Rembrandt Social Media, LP v. Facebook

Court excludes plaintiff expert testimony under Daubert, finding both the expert’s royalty base and rate determinations fatally flawed due to the expert’s inexact apportionment; in valuing damages, he failed to compensate only for the infringement caused ...

District Court puts a royalty value on standards essential patents for wireless technology

District Court judge refuses to grant new trial in Carnegie Mellon University v. Marvell Technology Group Ltd.

How can an analyst benchmark a patent license royalty?

How can a database of IP licenses act as a strategic resource in IP deal making?

Apple’s agency pricing maneuver costs it in price fixing suit

News, Views and Muse

Apple’s strategy in challenging Samsung’s rights with a standard essential patent comes to a head this week

Another musician wins back-pay settlement from when a download was a license

Royalty rate research now requires examination of the full text of comparable license agreements

What factors influence royalty rates in technology license agreements?

Royalty rate negotiators should not throw out the 25% rule

Royalty rates in pharma deals

Purpose for valuation of intangible property illustrates the need for royalty rate research

District Court Judge offers specific amounts that fit the terms criteria for “fair, reasonable and non-discriminatory”

Details of the lawsuit-settling Dupont and Monsanto cross-license agreement released

Market-based approach to valuing IP is enhanced by the existence of ktMINE

Pandora CEO to step down, but the company’s future depends upon Congress

So far, the Nash Bargaining Solution is no stand-alone substitute for the 25% rule-of-thumb

Royalty rates in pharma deals

What is a reasonable RAND royalty rate and range?

Moving marketing intangibles from a higher to a lower tax state is under international scrutiny